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The contact system of coagulation can be activated when in contact with biomaterials. As collagen is being tested in novel
biomaterials in this study, we have investigated how type IV collagen aﬀects plasma kallikrein and C1-inhibitor. Firstly, we showed
C1-inhibitor binds to type IV collagen with a Kd of 0.86μM. The eﬀects of type IV collagen on plasma kallikrein, factor XIIa, and
β-factor XIIa activity and on C1-inhibitor function were determined. Factor XIIa rapidly lost activity in the presence of type IV
collagen, whereas plasma kallikrein and β-factor XIIa were more stable. The rate of inhibition of plasma kallikrein by C1-inhibitor
was decreased by type IV collagen in a dose-dependent manner. These studies could be relevant to the properties of biomaterials,
which contain collagen, and should be considered in the testing for biocompatibility.
1.Introduction
Surface-dependent activation of factor XII and plasma pre-
kallikreinisnotbelievedtobeamajorcomponentofthenor-
mal in vivo blood coagulation activation process [1]. How-
ever, contact activation readily occurs in vitro,a sar e s u l to f
contact with surfaces such as glass, kaolin, and other mate-
rials and during procedures such as cardiopulmonary bypass
[2–5]. Under conditions such as these, factor XIIa could con-
vert factor XI to factor XIa and result in unwanted thrombin
generation. Therefore, it remains critical to understand the
mechanisms of contact activation, as this has important im-
plications for the thrombogenic properties and biocompat-
ibility of many materials. For example, novel biomaterials
are being developed for wound healing and drug delivery.
Notably, many of these materials contain collagen [6–9]. Al-
though collagens are naturally occurring molecules, if they
are present in nonphysiological situations or at elevated con-
centrations, they might have unwanted properties, such as
being thrombogenic [10].
C1-inhibitor is a proteinase inhibitor in the serpin family
which is an important physiological inhibitor of plasma
kallikrein and factor XIIa [11]. Previously we have shown
that C1-inhibitor can bind to type IV collagen and that this
can modulate the reaction with the complement proteinase
C1s [12]. As C1-inhibitor is the main inhibitor of plasma
kallikrein, we considered it to be important to investigate
the eﬀect of type IV collagen on the inhibition of plasma
kallikrein by C1-inhibitor. In this study we have investigated
binding of C1-inhibitor to type IV collagen in more detail
and studied the eﬀects of type IV collagen on plasma kallik-
reinandfactorXIIaactivitiesandontheinhibitionofplasma
kallikrein by C1-inhibitor.
2.MaterialsandMethods
2.1. Proteins and Reagents. Human plasma kallikrein, factor
XIIa,andC1swerefromEnzymeResearchLabs(SouthBend,
IN). β-factor XIIa was from Calbiochem (San Diego, CA,2 International Journal of Biomaterials
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Figure 1: Binding of C1-inhibitor to type IV collagen. The ﬁgure
shows the binding curve for biotinylated C1-inhibitor to type IV
collagen (×), BSA (), and the collagen binding with the sub-
traction of the BSA blank (). On the y- a x i si sc o u n t sp e rm i n u t e
(cpm).
USA). Human C1-inhibitor was from the Behringwerke
(Marburg, Germany). Inactive C1-inhibitor polymers were
removed by chromatography on Phenyl-Sepharose as de-
scribed previously [13]. Human types I, IV, and V collagen
and mouse type IV collagen were from Research Diagnostics
(Flanders,NJ,USA).ThechromogenicsubstratesS-2302(for
kallikrein, factor XIIa and β-factor XIIa) and Spectrozyme
C1-E(forC1s)werefromDiaPharma(Westchester,OH)and
American Diagnostica, (Greenwich, CT), respectively.
2.2. Binding of C1-Inhibitor to Type IV Collagen. Biotinyla-
tion of C1-inhibitor was carried out by incubating 0.5mL of
C1-inhibitor in PBS (1mg/mL) and 0.04mL of freshly pre-
pared biotinylation reagent (2.2mg NHS-LC-biotin (Pierce,
Rockford, IL) in 0.08mL water) on ice for 2.5h. Thereafter,
excess reagent was removed using a desalting PD10 column
(Pharmacia, Piscataway, NJ, USA), with protein detection at
280nm. To measure the binding aﬃnity, Immulon 2 ividas-
trip 96-well plates were coated with 100μLm o u s et y p eI V
collagen or bovine serum albumin at 10μg/mL in carbonate/
bicarbonate buﬀer at pH 7.5, for 18hrs at 4◦C. Wells were
blocked with 1% bovine serum albumin, 0.1% Tween 20, in
Tris-buﬀered saline, followed by washing with 0.1% Tween
20inTris-buﬀeredsaline.BiotinylatedC1-inhibitorwasadd-
ed to the wells at 1.9–125ng/mL. Binding was measured by
subsequent incubation with 125-I streptavidin, washing and
counting the individual wells in a gamma counter. Aﬃnity
was determined by Scatchard plot. To conﬁrm that binding
of C1-inhibitor to the type IV collagen was speciﬁc, the bio-
tinylated C1-inhibitor was displaced by use of an increasing
concentration of unlabelled C1-inhibitor.
Tryptophan ﬂuorescence was also used to analyze the in-
teraction between C1-inhibitor and type IV collagen, using a
PhotonTechnologyInternationalﬂuorimeter.Excitationwas
at 280nm, and emission was measured between 290nm and
400nm. Samples contained 1mg/mL C1-inhibitor, 6μg/mL
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Figure 2: Scatchard plot of C1-inhibitor binding to type IV col-
lagen. Analysis of the data from Figure 1. B/F is the ratio of
bound/free biotinylated C1-inhibitor.
type IV collagen, or a mixture of both, all in 3mL of 50mM
Tris-HCl, pH 7.4, 20mM NaCl.
2.3. Eﬀect of Collagen on Proteinase Activity. Plasma kallik-
rein, factor XIIa, and β-factor XIIa were assayed using S-
2302, and C1s was assayed using Spectrozyme C1-E, as de-
scribed previously [14]. To determine the eﬀect of collagen
on activity of the proteinases, kallikrein (30nM), factor XIIa
(0.649μM), β-factor XIIa (0.185μM), and C1s (0.46μM)
were incubated in 20mM Tris-HCl, pH 7.4, 150mM NaCl,
0.1% polyethylene glycol 8000 (with kallikrein, factor XIIa,
andβ-factorXIIa)or1mg/mLBSA(withC1s),at37◦Cinthe
absence of collagen, or with collagen at 20, 40, 60, 80, or
100μg/mL. Aliquots were removed at various times for assay
of residual proteinase activity.
2.4. Eﬀect of Type IV Collagen on Inhibition of Plasma Kallik-
rein by C1-Inhibitor. The inhibition of plasma kallikrein by
C1-inhibitor was measured under pseudo-ﬁrst-order condi-
tions using a discontinuous assay as described previously
[14]. Kallikrein (30nM) was incubated with a 10-fold excess
of C1-inhibitor in 20mM Tris-HCl, pH 7.4, 150mM NaCl,
0.1% polyethylene glycol 8000 at 37◦C in the absence of
collagen, or with collagen at 20, 40, 60, 80, or 100μg/mL.
Aliquots were removed at various times (from 30 seconds to
150 seconds) for assay of residual proteinase activity with S-
2302.
3. Results
3.1. Binding of C1-Inhibitor to Type IV Collagen. We have
shown previously in a qualitative assay that C1-inhibitor will
bind to type IV collagen [12]. To determine the aﬃnity for
this interaction, the binding of biotinylated C1-inhibitor to
immobilized type IV collagen was measured (Figure 1). The
aﬃnity was determined to be 0.86μM from the Scatchard
plot of this data (Figure 2). Conﬁrmation of the speciﬁcity of
binding of labeled C1-inhibitor was shown by displacementInternational Journal of Biomaterials 3
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Figure 3: Displacement of biotinylated C1-inhibitor from type
IV collagen. To conﬁrm speciﬁcity of binding of the biotinylated
C1-inhibitor to the immobilized collagen, the labeled protein was
displaced with unlabeled C1-inhibitor. On the y- a x i si sc o u n t sp e r
minute (cpm).
of the labeled protein by unlabeled protein (Figure 3). Fur-
ther evidence for the interaction is shown in Figure 4,w h i c h
shows the ﬂuorescence emission spectra of C1-inhibitor
alone, collagen alone, and a mixture of the two. Collagen had
very little ﬂuorescence due to the low tryptophan content.
The mixture of type IV collagen and C1-inhibitor showed
less ﬂuorescence than the C1-inhibitor alone, and less ﬂuo-
rescencethanwhentheindividualspectraoftypeIVcollagen
and C1-inhibitor were added together. Although no red or
blue shift occurred, this small quench is indicative of an in-
teraction between the two proteins. In addition, the magni-
tude of quench was dependent on the amount of collagen
used (not shown). However, as this quench was small, it
could not be reliably used to quantify binding aﬃnity.
3.2. Eﬀe c to fT y p eI VC o l l a g e no nP r o t e i n a s eA c t i v i t y . The ef-
fect of type IV collagen on the activity of kallikrein, factor
XIIa, or β-factor XIIa activity was determined. The pro-
teinases were incubated with increasing amounts of collagen,
andtheresidualactivitywasmeasured.Figure 5showsatime
course of loss of enzyme activity in the presence of 20 or
100μg/mL of type IV collagen. There was a rapid loss of fac-
tor XIIa activity, with 50% of the activity lost after 14.5
minutes in the presence of 20μg/mL of collagen and 50% of
the activity lost after 3 minutes in the presence of 100μg/mL
of collagen. This loss of activity is attributed to factor XIIa
adsorbing to the collagen [15]. In the absence of collagen,
only 10% of the activity was lost after 30 minutes of incu-
bation. With β-factor XIIa, the loss of activity was less, con-
sistent with β-factor XIIa not containing the surface binding
heavy chain. In the case of kallikrein, 20μg/mL of collagen
causedonlyaslightlossofactivityevenafter5hours,whereas
with 100μg/mL of collagen, there was an initial rapid de-
crease of activity to about 40%. A similar loss of kallikrein
activity by adsorption to surfaces has been observed previ-
ously[16,17],andsotheseresultsareentirelyconsistentwith
published data. As a control, the complement proteinase C1s
showed no loss of activity even after 6 hours with 100μg/mL
Table 1: Eﬀect of type IV collagen on the inhibition of plasma
kallikrein by C1-inhibitor.
Amount of type IV collagen
(μg/mL)
Second-order rate constant for
inhibition of kallikrein (M−1s−1)
0 16580
10 14370
20 13905
30 11650
40 10510
50 8450
oftypeIVcollagenindicatingthattheeﬀectsofcollagenwere
speciﬁc for the diﬀerent proteinases (data not shown).
3.3. Eﬀe c to fT y p eI VC o l l a g e no nt h eI n h i b i t i o no fP l a s m aK a -
llikrein by C1-Inhibitor. The rate constant for the inhibition
of kallikrein by C1-inhibitor in the presence of type IV colla-
gen was determined. Table 1 shows that there was dose-de-
pendent eﬀect on inhibition. As these assays were performed
over a short time frame (under 3 minutes), there was no loss
ofkallikreinactivityduringthistime(comparedtothelonger
times involved for loss of kallikrein activity seen in Figure 5).
The second-order rate constant for inhibition decreased by
50% with 100μg/mL of collagen. In other studies we have
shown that kallikrein inhibition by C1-inhibitor is also re-
duced when the inhibition reaction is carried out in type IV
collagen-coated microtiter plates [18].
4. Discussion
In this study we provide evidence that C1-inhibitor can bind
tightly to type IV collagen (Figures 1, 2, 3,a n d4). We also
show that type IV collagen caused a concentration-and time-
dependent loss of kallikrein and factor XIIa activities (Figure
5). However, by measuring the inhibition of kallikrein by
C1-inhibitor at early time points, we show that type IV
collagen can dramatically reduce the rate of inhibition. The
most likely explanation for these data is that the binding of
C1-inhibitor to collagen reduces the concentration of C1-
inhibitor available to react with kallikrein and so the rate
of inhibition drops. Given that the plasma C1-inhibitor con-
centration is ∼2μM, this is an interaction which potentially
couldoccurinvivo.However,whetherthishasanyregulatory
signiﬁcance for the contact system in vivo remains to be
determined, particularly as high concentrations of collagen
were used. Perhaps a more important consideration is that
the eﬀects of collagen on the activities of the proteins tested
indicate that studies with biomaterials should consider such
reactionsaspartoftheirscreeningforbiocompatibility,espe-
cially as high local concentrations of collagen would likely be
presentinsuchmaterials.Thuswewouldsuggestthatallma-
terialsthatusecollagen(especiallytypeIV)shouldbeevalua-
ted not only for their thrombogenic potential, but also for
more speciﬁc actions on the contact system proteinases and
C1-inhibitor, such as have been carried out with other bio-
materials [5, 6, 19–21].4 International Journal of Biomaterials
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Figure 4: The interaction of type IV collagen and C1-inhibitor assessed by ﬂuorescence spectroscopy. (a) The ﬂuorescence spectra of C1-
inhibitor alone (2nd line from top), type IV collagen alone (4th line, at bottom of ﬁgure), a mixture of type IV collagen and C1-inhibitor
(3rd line from top), and the individual spectra of C1-inhibitor alone and type IV collagen alone added together (1st line at top of ﬁgure). (b)
An ampliﬁed view of the same data at the apex of the peaks (between 295nm and 355nm).
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Figure 5: The time course of inactivation of kallikrein, factor XIIa,
andβ-factorXIIabytypeIVcollagen.Kallikreinwasincubatedwith
20μg/mL collagen ()o r1 0 0μg/mL collagen (), factor XIIa was
incubated with 20μg/mL collagen ()o r1 0 0μg/collagen (×), and
β-factor XIIa was incubated with 20μg/mL collagen (∗)o r5μg/mL
collagen(•).Attheindicatedtimes,asamplewasassayedforresidu-
al activity with S-2302. The activity is presented as the percentage of
the original activity prior to incubation. In the absence of collagen,
there was no loss of activity during the same time course.
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